OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis $0.01 +0.00 (+14.75%) As of 05/29/2025 01:58 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About Appili Therapeutics Stock (OTCMKTS:APLIF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Appili Therapeutics alerts:Sign Up Key Stats Today's Range$0.0108▼$0.014550-Day Range$0.01▼$0.0352-Week Range$0.01▼$0.04Volume357,000 shsAverage Volume95,155 shsMarket Capitalization$1.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAppili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.Read More… Appili Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScoreAPLIF MarketRank™: Appili Therapeutics scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Appili Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Appili Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Appili Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the outstanding shares of Appili Therapeutics have been sold short.Short Interest Ratio / Days to CoverAppili Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Appili Therapeutics has recently decreased by 24.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAppili Therapeutics does not currently pay a dividend.Dividend GrowthAppili Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the outstanding shares of Appili Therapeutics have been sold short.Short Interest Ratio / Days to CoverAppili Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Appili Therapeutics has recently decreased by 24.60%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Appili Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Appili Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Appili Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Appili Therapeutics' insider trading history. Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLIF Stock News HeadlinesAppili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.May 30 at 7:17 AM | globenewswire.comSaptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of MetronidazoleMay 20, 2025 | finance.yahoo.comElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it takes for the entire thing to burn right up. It’s a NEW internet service poised to disrupt the entire $3.2 trillion telecom industry. But you may only have this chance if you act before December 31st, 2025.May 30, 2025 | Banyan Hill Publishing (Ad)Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.May 19, 2025 | globenewswire.comAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to TularemiaMay 1, 2025 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZApril 28, 2025 | finanznachrichten.deAppili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™April 28, 2025 | globenewswire.comAppili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025April 2, 2025 | financialpost.comSee More Headlines APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed this year? Appili Therapeutics' stock was trading at $0.0280 on January 1st, 2025. Since then, APLIF stock has decreased by 50.0% and is now trading at $0.0140. View the best growth stocks for 2025 here. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) released its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2024Today5/30/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:APLIF CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.80 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-209.09% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$630,000.00 Price / Sales2.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-0.28Miscellaneous Outstanding Shares121,266,000Free Float106,908,000Market Cap$1.70 million OptionableNot Optionable Beta-0.51 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:APLIF) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.